Biocon has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).

The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income
countries (LMICs).

Biocon Biologics’ strong R&D and manufacturing capabilities have enabled the company to offer affordable biologics such as Trastuzumab and Pegfilgrastim to cancer patients in developed markets like the European Union and the United States.

Biocon Biologics aims to deliver substantial savings to healthcare systems by enhancing access and availability of these high-quality, affordable biosimilar cancer therapies in 25 countries in Africa and five countries in Asia currently covered under CAP, led by CHAI.

Biocon Biologics will initially supply Trastuzumab and Pegfilgrastim and will expand the arrangement to include
other biosimilars.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics, said, “Biocon Biologics has been in the forefront of a long-running crusade against cancer through its high quality affordable biosimilars. The collaboration with CHAI further strengthens our resolve to address the unmet patient needs in Asia and Africa for advanced cancer therapies through cost?effective alternatives to expensive reference biologics. This is an extension of our commitment to enable universal access to cancer patients following the initiation of our Mission 10 cents to provide insulins for people with diabetes in LMICs.”

Dr Christiane Hamacher, CEO, Biocon Biologics, said, “We are extremely proud to collaborate with CHAI to realise our mission of enabling universal access to quality cancer care. Biocon Biologics is reimagining access to biologicsin LMICs through strategic partnerships with global
health organisations. We are committed to reducing the high cost of cancer care for
healthcare systems through our biosimilars and are pleased to address the needs of patients in Africa and Asia through the Cancer Access Partnership (CAP).”

Dr Ian Barton, CEO, CHAI, stated, “Expanding the Cancer Access Partnership to include high quality biologics from Biocon takes us another step closer to ensuring that cancer patients have access to the quality medications that they need at an affordable price, no matter where they live. We welcome the new commitments and we look forward to partnering to bring these
high-quality medicines to patients.”

As a committed global player in Biosimilars, Biocon Biologics is leveraging its science, scale and expertise to shift the access paradigm for patients in need of biosimilars across the globe.

Biocon Biologics has developed monoclonal antibodies and therapeutic proteins for oncology, which are having a significant impact in the area of cancer care in several developed and emerging markets by providing high-quality, cost-effective alternatives to expensive reference biologics.

Biocon Biologics has commercialised three biosimilars -Trastuzumab, Pegfilgrastim and Insulin Glargine in the US. Its Trastuzumab has received regulatory approvals in over 60 countries and has been commercialised in US, EU, Canada, Australia and selected Most of the World (MoW) markets. Its Pegfilgrastim has approvals in ~40 countries and is commercially available in US, EU, Canada and Australia.